[go: up one dir, main page]

ATE517125T1 - ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN - Google Patents

ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN

Info

Publication number
ATE517125T1
ATE517125T1 AT99903332T AT99903332T ATE517125T1 AT E517125 T1 ATE517125 T1 AT E517125T1 AT 99903332 T AT99903332 T AT 99903332T AT 99903332 T AT99903332 T AT 99903332T AT E517125 T1 ATE517125 T1 AT E517125T1
Authority
AT
Austria
Prior art keywords
antibodies
receptor
ßdeath
kits
diagnosis
Prior art date
Application number
AT99903332T
Other languages
English (en)
Inventor
Anan Chuntharapai
Kyung Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22107878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517125(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE517125T1 publication Critical patent/ATE517125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99903332T 1998-01-26 1999-01-25 ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN ATE517125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7248198P 1998-01-26 1998-01-26
PCT/US1999/001437 WO1999037684A1 (en) 1998-01-26 1999-01-25 Antibodies to death receptor 4 (dr4) and uses thereof

Publications (1)

Publication Number Publication Date
ATE517125T1 true ATE517125T1 (de) 2011-08-15

Family

ID=22107878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903332T ATE517125T1 (de) 1998-01-26 1999-01-25 ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN

Country Status (12)

Country Link
EP (1) EP1053256B9 (de)
JP (1) JP2002500877A (de)
AT (1) ATE517125T1 (de)
AU (1) AU2338299A (de)
CA (1) CA2318405C (de)
CY (1) CY1111863T1 (de)
DK (1) DK1053256T3 (de)
ES (1) ES2368823T3 (de)
HK (1) HK1033582A1 (de)
IL (1) IL137176A0 (de)
PT (1) PT1053256E (de)
WO (1) WO1999037684A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
JP4450870B2 (ja) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
AU4984300A (en) * 1999-05-06 2000-11-21 Vishva M Dixit Death domain containing receptor 4
ATE429450T1 (de) * 1999-05-28 2009-05-15 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
EP1658859A1 (de) * 1999-06-09 2006-05-24 Genentech, Inc. APO-2L Rezeptor-Agonist und CPT-11 Synergie-Effekt
PT1192185E (pt) * 1999-06-09 2006-11-30 Genentech Inc Sinergismo de agonista do receptor de apo-2l e cpt-11
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
AU2001279055A1 (en) * 2000-07-27 2002-02-13 Genentech, Inc. Apo-2L receptor agonist and CPT-11 synergism
AU2001297702A1 (en) * 2000-11-08 2002-10-15 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002256895B2 (en) * 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
MXPA03010747A (es) * 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
IL159527A0 (en) 2001-07-03 2004-06-01 Genentech Inc Human dr4 antibodies and uses thereof
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
US20060141561A1 (en) 2002-06-24 2006-06-29 Kelley Robert F Apo-2 ligand/trail variants and uses thereof
EP1534336A4 (de) * 2002-08-15 2005-12-14 Human Genome Sciences Inc Antikörper, die immunospezifisch an trail-rezeptoren binden
CN101274098A (zh) 2003-05-30 2008-10-01 健泰科生物技术公司 利用抗-vegf抗体的治疗
ZA200701657B (en) 2004-08-06 2008-09-25 Genentech Inc Assays and methods using biomarkers
CA2575152A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
WO2006029275A2 (en) * 2004-09-08 2006-03-16 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AU2006210838B2 (en) 2005-02-02 2011-10-20 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
CN101365951B (zh) 2005-08-16 2013-09-11 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
EP2379585A2 (de) 2008-10-10 2011-10-26 Anaphore, Inc. Trail-r1 und trail-r2 bindende polypeptide
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
EP2704735A1 (de) 2011-05-03 2014-03-12 Genentech, Inc. Vaskuläre disruptoren und ihre verwendung
EP3323428A1 (de) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selektive c-flip-hemmer als antikrebsmittel
EP4071167A4 (de) 2019-12-03 2024-03-06 Shanghai Jiao Tong University School of Medicine Antikörper-fc-region mit erhöhter fcgriib-affinität
EP3910331A1 (de) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1368292A (en) * 1991-03-11 1992-10-06 Sheila Drover Murine monoclonal antibodies recognizing polymorphic determinants of hla
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
WO1998000543A1 (en) * 1996-07-03 1998-01-08 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
DE69740038D1 (de) * 1996-07-12 2010-12-16 Genentech Inc
JP4450870B2 (ja) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合

Also Published As

Publication number Publication date
DK1053256T3 (da) 2011-10-03
CA2318405C (en) 2014-01-07
IL137176A0 (en) 2001-07-24
EP1053256B1 (de) 2011-07-20
AU2338299A (en) 1999-08-09
HK1033582A1 (en) 2001-09-07
CY1111863T1 (el) 2015-11-04
ES2368823T3 (es) 2011-11-22
WO1999037684A1 (en) 1999-07-29
JP2002500877A (ja) 2002-01-15
EP1053256B9 (de) 2012-01-18
CA2318405A1 (en) 1999-07-29
EP1053256A1 (de) 2000-11-22
PT1053256E (pt) 2011-09-28

Similar Documents

Publication Publication Date Title
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
WO2004011611A3 (en) Taci antibodies and uses thereof
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
DE69501591D1 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
NO20061736L (no) Krystallform av epotilon B
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
BR0107691A (pt) Sapogeninas substituìdas e seu uso
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
ATE189897T1 (de) Antikörper gegen das prorenin profragment, reninaktive substanz die diese enthält und prorenintest die diese verwendet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053256

Country of ref document: EP